Also listed on Allergan, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Mar 14, 2033 · Medium confidence
20-year base term ends Mar 14, 2033
Why Medium: A parent in the chain could not be resolved.
Mar 14, 2013
Mar 14, 2033
Apr 26, 2022
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 14, 2013, when application 13/829,984, the earliest non-provisional in its chain, was filed (this one was filed Sep 22, 2021); a parent in its chain could not be resolved (the next row) | Mar 14, 2033 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,188,632, US 11,007,179, US 11,090,291, US 11,160,792, US 11,229,627, US 9,675,587) | resolves to Mar 14, 2033, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 14, 2033 | Medium confidence |
Partial family
| US 9,675,587 | In force Mar 2033 | Mar 2033 |
| US 10,188,632 | In force Mar 2033 | Mar 2033 |
| Application 16/213,083 | No file history here not computed | not computed |
| Application 16/459,947 | No file history here not computed | not computed |
| Application 16/795,044 | No file history here not computed | not computed |
| US 11,007,179 | In force Mar 2033 | Mar 2033 |
| US 11,090,291 | In force Mar 2033 | Mar 2033 |
| US 11,160,792 | In force Mar 2033 | Mar 2033 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Oct 27, 2021 Reel 57932, frame 492 | Jans, Eugeen Maria Jozef; Heyns, Philip Erna H.; Ceulemans, Jens Jozef | Janssen Pharmaceutica N.V. | Assignment of Assignor's Interest |
| Oct 27, 2021 Reel 57932, frame 529 | Costello, Tim | Furiex Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Oct 27, 2021 Reel 57932, frame 577 | Janssen Pharmaceutica N.V. | Furiex Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Oct 27, 2021 Reel 57940, frame 907 | Furiex Pharmaceuticals, Inc. | Furiex Pharmaceuticals, LLC | Change of Name |
| Oct 27, 2021 Reel 57932, frame 679 | Furiex Holdings Unlimited Company | Forest Tosara Limited | Assignment of Assignor's Interest |
| Oct 27, 2021 Reel 57940, frame 912 | Furiex Pharmaceuticals, LLC | Furiex Holdings Unlimited Company | Assignment of Assignor's Interest |
| Oct 27, 2021 Reel 57932, frame 834 | Forest Tosara Limited | Allergan Holdings Unlimited Company | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 10,188,632, US 11,007,179, US 11,090,291, US 11,160,792, US 11,229,627, US 9,675,587, ends no earlier than this term, so it caps nothing.